What question did this study set out to answer?

Evaluate the effectiveness of an inactivated trivalent avian influenza vaccine against H5N1 in layers.

synapse

⌘+K

synapse

⌘+K

March 15, 2026Open Access

Inactivated trivalent avian influenza vaccine protects layers from mortality and reduces shedding after challenge with highly pathogenic avian influenza H5N1 2022 isolate from Peru

Key Points

Evaluate the effectiveness of an inactivated trivalent avian influenza vaccine against H5N1 in layers.
Administered MEFLUVAC™ H5 PLUS 8 vaccine to hens at seven weeks of age.
Challenged birds with highly pathogenic H5N1 isolated from Peru.
Monitored clinical signs and analyzed serum samples for antibodies.
Quantified virus shedding via PCR from tracheal and cloacal swabs.
Vaccine reduced mortality and clinical disease in vaccinated hens.
Significantly lower viral shedding post-challenge observed in vaccinated hens.

Abstract

The inactivated trivalent avian influenza (AI) vaccine, MEFLUVAC™ H5 PLUS 8, was administered intramuscularly to hens at seven weeks of age, and the birds were challenged with highly pathogenic avian influenza virus (HPAIV) isolated in Peru (H5N1) in 2022. Birds were observed for clinical signs of disease and serum samples were analyzed for H5-specific antibodies. Virus shedding was quantified by PCR and prevalence of replicating virus was determined from tracheal and cloacal swabs. The results indicate that the vaccine is effective in preventing mortality and clinical disease and reducing viral shedding after challenge with an HPAI H5N1 isolate that shares 96.7% sequence identity with a fraction of the commercial vaccine.

Inactivated trivalent avian influenza vaccine protects layers from mortality and reduces shedding after challenge with highly pathogenic avian influenza H5N1 2022 isolate from Peru

Key Points

Abstract

Cite This Study

Also Consider

Also Consider